BioMarin said Friday it would purchase Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn of the century.
With the deal, BioMarin will acquire two approved drugs, one for Pompe disease and one for Fabry disease, that took in $600 million over the past year and that the company said are poised for growth.
BioMarin will pay $14.50 per share, or a 33% premium over Amicus’s closing price on Thursday.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
